SPA
DFTX

Sherbrooke Park Advisers’s Definium Therapeutics DFTX Stock Holding History

Sherbrooke Park Advisers’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,827
Closed -$78.7K – 1015
2024
Q3 		$78.7K Buy
+13,827
New +$96.2K 0.02% 852

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's DFTX Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 13,827 shares — an estimated $78.7K sold.

Sherbrooke Park Advisers first reported a position in DFTX in Q3 2024 and held it in 1 quarter. The position peaked at $78.7K in Q3 2024. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,827 Definium Therapeutics shares in Q4 2024, an estimated $78.7K.
  • Sherbrooke Park Advisers first reported a position in Definium Therapeutics in Q3 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Definium Therapeutics position peaked at $78.7K in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.